Loading…
Loading…
BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assenagon Asset Management S.A. trimmed its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) by 24.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,339,560 shares of the biotechnology company's stock after selling 422,526 shares during
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Relay Therapeutics (NASDAQ: RLAY - Get Free Report) and BioMarin Pharmaceutical (NASDAQ: BMRN - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk. Analyst Recommendations This is a summary of recent
New analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced it will present new data from 13 studies at the American Society for Bone and Mineral Research 2026 Annual Meeting (ASBMR) in Boston, including results from studies of VOXZOGO® (vosoritide) in children with achondroplasia and hypochondroplasia.
BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.
Ms. Bauer Brings More Than 25 Years of Experience in Human Resources, Across Biotechnology and Technology Industries Appointment Effective Oct. 5, 2026 SAN RAFAEL, Calif., Oct. 5, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that Cara Bauer, Ph.D.
A BioMarin combination therapy helped adults with late-onset Pompe disease maintain walking distance over five years of continuous therapy. Respiratory function remained relatively stable, with no new safety signals identified.